Acne vulgaris (often simply called acne) is a chronic inflammatory disorder of the pilosebaceous unit (the follicle and its oil gland). It is extremely common in adolescents but can persist or begin in adulthood. Although it is frequently discussed as a cosmetic problem, acne has a well-defined biological basis involving follicular keratinization, sebum overproduction, Cutibacterium acnes (formerly Propionibacterium acnes)–driven inflammation, and dysregulated innate and adaptive immune responses. Clinically, it presents with comedones (open and closed), papules, pustules, nodules, and sometimes cysts. Severity ranges from mild comedonal acne to severe nodulocystic disease with scarring.
The core pathogenic sequence begins with abnormal follicular epithelial differentiation. In susceptible individuals, follicular keratinocytes proliferate and shed poorly, forming microcomedones that evolve into visible comedones. Simultaneously, androgen signaling increases sebum production. Increased lipid availability alters the follicular environment and promotes colonization and activity of C. acnes. This bacterium is not the sole cause; rather, its virulence factors and metabolic products trigger inflammatory cascades. C. acnes stimulates toll-like receptors and other innate immune pathways, leading to increased cytokine release such as interleukin-1β, interleukin-8, and tumor necrosis factor–related signals. Inflammation then damages follicular walls and contributes to papules, pustules, and deeper lesions.
A major determinant of long-term outcomes is whether lesions become deep and prolonged. Persistent inflammation can lead to dermal matrix disruption and subsequent scarring (atrophic, hypertrophic, or keloidal). Post-inflammatory hyperpigmentation (PIH) is also common, especially in darker skin types, and may be mistaken for persistent acne. Understanding this helps guide treatment goals: preventing new lesions, controlling existing inflammation, minimizing scarring risk, and addressing pigmentation sequelae.
Evidence-based acne management is usually staged and tailored to lesion type and severity. For comedonal and mild inflammatory acne, topical retinoids are foundational because they normalize follicular keratinization and help prevent new microcomedones. Common retinoid mechanisms include increased cellular turnover and reduced adhesion of keratinocytes. Topical benzoyl peroxide reduces C. acnes through oxidation and has a rapid anti-inflammatory effect; importantly, it also helps prevent antibiotic resistance when combined with topical or systemic antibiotics. Topical antibiotics (often clindamycin) can reduce inflammatory lesions but should generally be used in combination with benzoyl peroxide and for limited durations to reduce resistance pressure.
For moderate to severe acne, systemic therapies may be indicated. Oral antibiotics (e.g., doxycycline or minocycline) target inflammatory pathways and decrease bacterial load. They are typically paired with benzoyl peroxide or a topical retinoid. Hormonal therapies—especially in women with acne linked to androgen sensitivity—may include combined oral contraceptives or anti-androgen agents. These options reduce sebum production by altering androgen effects on sebaceous glands.
For severe nodulocystic acne, scarring acne, or refractory disease, isotretinoin is a highly effective retinoid that reduces sebum production dramatically, normalizes follicular keratinization, and exerts anti-inflammatory effects. Because isotretinoin is teratogenic and can affect hepatic function and lipids, it requires careful monitoring and risk management according to local regulations.
Adjunctive strategies can enhance outcomes. Gentle skin care, non-comedogenic moisturizers, and sunscreen can reduce irritation and improve adherence while mitigating PIH. Over-exfoliation or harsh scrubbing can worsen barrier dysfunction and inflammation. In some patients with persistent lesions or refractory inflammation, dermatologic procedures such as intralesional corticosteroids for individual nodules, chemical peels, or laser/light therapies may be considered, though they are adjunctive rather than primary replacements for evidence-based topical/systemic regimens.
Acne also has psychological impacts. Visible lesions can contribute to reduced self-esteem, anxiety, social withdrawal, and depressive symptoms. This effect can be independent of clinical severity. Clinicians therefore should screen for psychosocial distress and counsel patients on realistic timelines: noticeable improvement often takes 6–12 weeks for many therapies, with maximal benefits sometimes requiring longer. Adherence, proper application, and gradual ramp-up of irritant-prone agents improve tolerability.
In summary, acne vulgaris is driven by abnormal follicular keratinization, androgen-related sebum excess, C. acnes–associated inflammation, and immune dysregulation. Effective care targets these mechanisms with topical retinoids, benzoyl peroxide, and combination antibiotic strategies when needed, while moderate to severe disease may require oral antibiotics, hormonal modulation, or isotretinoin. Early, mechanism-based treatment reduces lesion burden, lowers scarring risk, and helps address pigmentation sequelae, while acknowledging acne’s substantial psychosocial burden. Source: @Oxecureofficial (Source Link provided)
Oxe’cure: ✨พี่อ๊อกซี่ พกความน่ารักของน้องโฟ้ดโฟ้ดมาเสิร์ฟให้มัมหมีทุกคนค่าาา กับ Behind The Scene Ep.3 4️⃣💚 🥰พี่อ๊อกซี่ขอขอบคุณสำหรับไลก์&แชร์ทุกกำลังใจทุกช่องทางที่มัมหมีทุกคนส่งมาให้นะคะ💚 📍อยากหน้าใสไกลสิวเหมือนน้องโฟ้ดโฟ้ดมาซื้อ Oxe’cure ได้ที่ 7-11, Watsons, Boots, Beautrium,. #breaking
— @Oxecureofficial May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
